The predecessor of Tiancheng, the Pharmacological Research Team of Tianjin Institute of Materia Medica, began exploring methods for studying the efficacy of cardiovascular and cerebrovascular drugs as early as the 1960s. Over the decades, they have participated in the development of dozens of new drugs, involving the treatment of many diseases such as hypertension, angina pectoris, arrhythmia, myocardial infarction, heart failure, thrombosis, and stroke. In 1993, the Tianjin Hypertension Pharmacology Laboratory of the National Medical Administration was established here, which was the first ministerial level key laboratory established by the National Medical Administration. In recent years, more than 100 pharmacological research projects on cardiovascular and cerebrovascular drugs have been completed, helping to obtain dozens of clinical approvals.

Advantageous Technology

• Establishment of in vitro and in vivo pharmacological models involving multiple genera;
• Using color Doppler ultrasound to perform non-invasive, dynamic, long-term, and repeated measurements of cardiac configuration and function indicators;
• Using remote control, real-time detection system, physiological signal recording system, and blood flow recording system to perform long-term dynamic monitoring of hemodynamics in awake and anesthetized animals;
• The use of a real-time automatic data analysis system can achieve automatic real-time analysis of data;
• Detect hemorheological indicators such as blood viscosity, coagulation, and platelet aggregation using a blood viscosity analyzer, coagulation factor analyzer, and platelet aggregation analyzer;
• Conduct ex vivo cardiac vascular perfusion experiments using an ex vivo perfusion device.

Research Model

• In vitro myocardial cell pathological model
• In vitro working heart and vascular drug efficacy screening model
• Myocardial ischemia-reperfusion models in rat and dog
• Hemodynamic Study of rat and dog
• Rat model of cerebral ischemia
• A model of reduced cerebral blood flow in dog
• Rat model of leptomeningeal microcirculation disorder
• Rabbit ischemic brain metabolism model
• Thrombosis model
• In vitro thrombus model
• Myocardial infarction model
• Stroke model
• Pulmonary embolism model
• Venous bypass thrombosis model
• Retinal artery thrombosis model
• Cerebral embolism model
• Stable and unstable angina model
• Platelet arterial deposition model
• Fibrin deposition model
• Hypertension models in rat and dog
• Myocardial hypertrophy model
• Heart failure model